Follow the finding back to the source.
A link is useful when it helps answer the question you’re reading about. Here are the sources cited across SD Peptides, with a note on what each adds and where its answer stops.
Human results and what happened later
Semaglutide in adults with overweight or obesity
A human trial with a dummy treatment for comparison. We use the average weight change and the share reaching a goal; neither tells everyone’s story.
Weight regain after semaglutide withdrawal
A smaller group followed after the medicine and lifestyle support stopped. The regain figure describes people previously taking semaglutide; it does not decide a person’s treatment length.
Semaglutide prescribing information
The safety warnings include tumours in thyroid C cells seen in rodents. Whether that happens in humans is unknown; both parts belong in the explanation.
Healing claims and the exact substance
FDA review of BPC-157
The FDA separates small human reports from animal work. Those human studies can’t establish safety, even when their reports sound reassuring.
BPC-157 and a cut Achilles tendon in rats
An experiment on cut tendons in rats. It doesn’t tell us when a person with an everyday injury will move comfortably again.
FDA review of TB-500
The review found no published human TB-500 studies. It also explains why TB-500 can’t borrow findings about full-length thymosin beta-4.
Cells, skin and mice
GHK-Cu and collagen production in cell cultures
A finding about collagen production in skin cells grown in a dish. That isn’t a measured change in someone’s skin.
Copper tripeptide on skin after laser resurfacing
After laser treatment, the GHK-Cu group reported more satisfaction. The measured skin outcomes did not establish a statistically clear benefit; the small headcount leaves room for uncertainty.
MOTS-c in cells and mice
Mice gained less weight on a high-fat diet and handled sugar better. The study doesn’t give us a human weight-loss result.
FDA review of MOTS-c
The FDA found no human data to establish benefit or safety. An explanation of how MOTS-c might work can’t replace those missing results.
KPV uptake and intestinal inflammation
Work on cells and bowel inflammation caused in mice. The mouse finding leaves the question about human bowel disease unanswered.
FDA review of KPV
The FDA found no human studies of KPV. Side effects remain unknown; possible immune reactions aren’t measured harms in people.
Approval and safety context
FDA safety concerns and withdrawn nominations
The page current as of April 22, 2026 lists withdrawn nominations alongside safety concerns. Withdrawal means no approval or clearance, and it gives no individual move dates.
FDA explanation of compounded drug risks
A compounded medicine is prepared for a particular patient’s medical needs. Those medicines aren’t FDA-approved, even when an approved medicine contains the same ingredient.
Read the link with its sentence
We check whether the people or animals, substance and outcome match the claim. A paper on a related substance isn’t a substitute. If the source leaves the answer open, the sentence needs to leave it open too.
Return to the opening examples or our page on ranges to put those questions to work. The teaching examples add no results to these studies.